文献速递心律失常

2026 AHA/ACC 心房颤动患者临床绩效与质量测量指标解读

2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association.
PubMed 文献 · J Am Coll Cardiol · 2026-08-17

该报告由美国心脏病学会/美国心脏协会写作委员会基于《2023 ACC/AHA/ACCP/HRS 心房颤动诊断与管理指南》制定,提出 5 项绩效测量指标和 16 项质量测量指标。绩效指标适用于公开报告或按绩效付费项目,关注新诊断房颤患者的基础临床评估、卒中风险记录和适宜抗凝。质量指标覆盖健康公平、抗心律失常/抗凝优化、共享决策及射血分数降低心衰患者的导管消融等内容。

要点

  • 新诊断房颤患者应完成基础临床评估并记录卒中风险
  • 有适应证的患者应接受适宜的口服抗凝治疗进行卒中二级预防
  • 射血分数降低的心衰合并房颤患者,适宜者可考虑导管消融

核心结论

  • 该绩效与质量测量指标旨在提升所有房颤患者群体的医疗质量与公平性,推动遵循最强级别指南推荐。

研究设计与样本

  • 写作委员会从《2023 ACC/AHA/ACCP/HRS 房颤诊断与管理指南》的 1 类或 3 类最强推荐中选取测量指标。
  • 共制定 5 项绩效测量指标,适用于公开报告或按绩效付费项目。
  • 共制定 16 项质量测量指标,供临床医生和医疗机构用于质量改进。

主要发现

  • 绩效指标强调对房颤各阶段患者进行二级预防,记录卒中风险并在有指征时提供适宜抗凝。
  • 质量指标涵盖测量和解决健康不公平、优化抗心律失常或抗凝治疗。
  • 质量指标还包括就室率控制与节律控制策略进行共享决策。
  • 质量指标提出对合并射血分数降低心衰的适宜房颤患者考虑导管消融。

关键数值与推荐

  • 绩效测量指标共 5 项,适用于公开报告或按绩效付费项目。
  • 质量测量指标共 16 项,适用于临床质量改进。
  • 测量指标选自 2023 年房颤指南的 1 类或 3 类推荐。
  • 新诊断房颤患者需完成基础临床评估。

临床怎么用

  • 临床医生应对新诊断房颤患者完成基础临床评估,并记录卒中风险评分。
  • 有抗凝指征的房颤患者应启动适宜的口服抗凝治疗。
  • 对合并射血分数降低心衰的适宜房颤患者,可考虑转诊评估导管消融。
  • 临床实践中应与患者就室率控制和节律控制策略开展共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is increasing in incidence, prevalence, and lifetime risk, and contributes to substantially greater health care costs and increased risks of stroke, heart failure, and mortality. Improving adherence to evidence-based recommendations equitably in AF is critical to advancing clinical care, patient outcomes, and public health. The writing committee developed a comprehensive set of 5 performance measures, which are appropriate for public reporting or pay-for-performance programs, and 16 quality measures, which are useful to clinicians and health care organizations for quality improvement. The writing committee selected the measures from the strongest recommendations (Class 1 or 3) in the "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation." The purpose of the writing committee's performance measures is meant to ensure that patients with newly diagnosed AF receive a basic clinical evaluation, with an emphasis on secondary prevention for patients at all stages of AF, documenting stroke risk, and, if indicated, providing appropriate anticoagulation. AF quality measures cover a variety of topics including measuring and addressing health inequities, optimizing antiarrhythmic or anticoagulant treatment, engaging in shared decision-making for rate- versus rhythm-control strategies, and, in appropriate patients, offering catheter ablation for those with heart failure with reduced ejection fraction. The performance and quality measures are intended to advance the quality and equity of AF care across all patient populations with AF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Benjamin, Marcus, Hess, et al. 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol. 2026. PMID: 42608866. doi:10.1016/j.jacc.2026.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。